Moderna Cuts Forecast, Misses Estimates as Orders Delayed

Moderna Inc. earnings offered a preview into the future of Covid-19 vaccine sales, and so far it doesn’t look pretty. The company cut its vaccine sales forecast for the year and gave its first hint at 2023 as interest in immunization fades amid the fading pandemic concerns. While analysts were largely anticipating a disappointing quarter, the miss comes only days after rival Pfizer Inc. raised its vaccine guidance for the year.